Cara Therapeutics (CARA) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

CARA Cara Therapeutics

Watchlist

0.288
-0.002-0.66%

Close Nov 27 16:00 ET

0.290
+0.002+0.52%

Post 19:21 ET

15.80MMarket Cap-164P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Express News | Cara Therapeutics Inc - Receives Non-Compliance Notice From Nasdaq on Minimum Stockholders’ Equity Requirement
ReutersNov 22 16:12 ET
Cara Therapeutics Third Quarter 2024 Earnings: Beats Expectations
Yahoo FinanceNov 17 07:32 ET
Cara: Q3 Earnings Snapshot
Yahoo FinanceNov 14 19:31 ET
Cara Therapeutics | 10-Q: Q3 2024 Earnings Report
SECNov 14 16:17 ET · Announcements
Earnings Week Ahead: DIS, BABA, JD, CSCO, HD, OXY, SU, SHOP, AMAT, SPOT, and More
Seeking AlphaNov 10 08:01 ET
Express News | CSL Limited Reports 13.5% Stake in Cara Therapeutics Inc as of Oct 23 - SEC Filing
ReutersOct 30 16:23 ET

Comments

Jaguar8

Oct 30 15:24

NEWS

$Cara Therapeutics (CARA.US)$
CSL Limited Reports 13.5% Stake in Cara Therapeutics Inc as of Oct 23 - SEC Filing

Jaguar8

Jun 12 15:02

NEWS

$Cara Therapeutics (CARA.US)$
Cara Therapeutics Announces Outcome of Part A of KOURAGE-1 Study Evaluating Oral Difelikefalin in Notalgia Paresthetica
Cara Therapeutics announced disappointing results from Part A of their KOURAGE-1 study, evaluating oral difelikefalin for notalgia paresthetica (NP). The drug did not show meaningful clinical benefit over placebo at any dose, leading the company to discontinue the clinical program in NP. The Phase 2/3 trial involved 214 patients, and despite the...

Sean Parker

May 1 05:51

Hope it goes well

$Cara Therapeutics (CARA.US)$
CERo Therapeutics, Inc. Presents Encouraging Preclinical Data for AML on CER-1236 at Stanford Drug Discovery Symposium Highlighting Tumor Elimination and Manufacturing Attributes30/04/2024 09:00AM ET
SOUTH SAN FRANCISCO, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (NASDAQ:CERO) ("CERo") an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic a...

Moomoo AI

Dec 31, 2023 08:15

Cara Therapeutics' low P/S ratio reflects its declining revenues and bleak future growth projection. Per investors, the company's future may not yield a significant revenue improvement.